SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Weir H, Thun M, Hankey B, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003; 95: 1276-1299.
  • 2
    Chuman Y, Bergman A, Ueno T, et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett. 1999; 462: 129-134.
  • 3
    Garcia M, Ward E, Center M, et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
  • 4
    Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
  • 5
    Travis W. Pathology of lung cancer. Clin Chest Med. 2002; 23: 65-81.
  • 6
    Ueno T, Linder S. Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. BMJ. 2003; 88: 1229-1233.
  • 7
    Carlson J. Erlotinib in nonsmall-cell cancer: a review of the clinical and economic evidence. Expert Rev Pharamacoecon Outcomes Res. 2009; 9: 409-416.
  • 8
    Inamura K, Ninomiya H, Ishikawa Y, et al. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 2010; 134: 66-72.
  • 9
    Miller V, Dris M, Shah N, et al. Bronchioalveolar pathologic subtype and smoking history predict sensitivity of gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol. 2004; 22: 1103-1109.
  • 10
    Hseih R, Lim K, Kuo H, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in nonsmall-cell lung cancer. Chest. 2005; 128: 217-321.
  • 11
    Lau S, Luthringer D, Eisen R. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002; 10: 97-102.
  • 12
    Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008; 132: 384-396.
  • 13
    Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010; 23: 654-661.
  • 14
    Bishop J, Sharma R, Illei P. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010; 41: 20-25.
  • 15
    Ueno T, Linder S, Na C, et al. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem. 2004; 279: 16178-16184.
  • 16
    DeFelice M, Siberschmidt D, DiLaura R, et al. TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. J Biol Chem. 2003; 278: 35574-35583.
  • 17
    Lin S, Na C, Akinbi H, et al. Surfactant protein B (SP-B)−/− mice are rescued by restoration of SP-B expression in alveolar type II cells but not Clara cells. J Biol Chem. 1999; 274: 19168-19174.
  • 18
    Schultz H, Kahler D, Brancheid D, et al. TKTL1 is overexpressed in a large portion of nonsmall cell lung cancer specimens. Diagn Pathol. 2008; 12: 1-5.
  • 19
    Hirano T, Fujioka K, Franzen B, et al. Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features. Br J Cancer. 1997; 75: 978-985.
  • 20
    Schauer-Vukasinovic V, Bur D, Kling D, Grüninger F, Giller T. Human napsin A: expression, immunohistochemical detection and tissue localization. FEBS Lett. 1999; 462: 135-139.
  • 21
    Demjeck A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol. 2007; 35: 493-497.
  • 22
    Hiroshima K, Iyoda A, Shida T, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006; 19: 1358-1368.
  • 23
    Perner S, Wagner P, Soltermann A, et al. TTF1 expression in nonsmall cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol. 2009; 217: 65-72.
  • 24
    Rossi G, Pelosi G, Barbareshci M, et al. A reevaluation of the clinical significance of histological subtyping of non small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009; 17: 206-218.